港股異動 | 利好疊加 先聲藥業(2096.HK)再度大漲逾14%創階段新高
格隆匯5月27日丨昨日大漲的先聲藥業(2096.HK)今日再度拉昇漲超14%,現報10.6港元創7個月新高價,總市值近300億港元。全球規模最大,學術水平最高且最具影響力腫瘤臨牀學術盛會之一的美國臨牀腫瘤學會( ASCO )年會在6月初召開,公司將於ASCO年會公佈多項抗腫瘤藥物臨牀進展。另外,先聲藥業與G1骨髓保護新藥Trilaciclib快速實現首例患者入組,距Trilaciclib在2月13日獲美國FDA批准上市僅100天。如今,先聲藥業通過“自主研發+對外合作”,不僅在中樞神經領域建立了較為多病種全病程的管線佈局,在腫瘤和免疫領域也規劃起了宏大版圖,旗下50餘種處於不同研發階段的在研產品正逐步按計劃兑現進度。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.